文献速递肿瘤 PET/CT核素与放射性配体治疗

混合放射性荧光示踪剂在前列腺癌前哨淋巴结Ⅱ期随机试验中的结果优于两种示踪剂简单相加

A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-04-10

混合组荧光淋巴结数更少(310 vs 665,p<0.001),但肿瘤阳性淋巴结数无显著差异(44 vs 33,p=0.470),荧光淋巴结中肿瘤阳性率混合组更高(7.4% vs 2.6%,p=0.002),提示混合示踪剂阳性预测值更优。

要点

  • 混合组荧光淋巴结数310枚少于序贯组665枚(p<0.001)。
  • 两组肿瘤阳性淋巴结数无显著差异(44 vs 33,p=0.470)。
  • 混合组荧光淋巴结肿瘤阳性率7.4%高于序贯组2.6%(p=0.002)。

核心结论

  • 与序贯示踪剂方法相比,混合示踪剂ICG-99mTc-纳米胶体提高了肿瘤阳性淋巴结的阳性预测值,同时减少了荧光淋巴结数量。
  • 作者认为混合示踪剂ICG-99mTc-纳米胶体为前列腺癌患者淋巴结分期提供了最可靠且创伤最小的方法。

研究设计与样本

  • 前瞻性随机Ⅱ期试验,纳入2012年Briganti列线图淋巴受累风险>5%且计划行前列腺切除术的前列腺癌患者。
  • 患者按1:1随机分为混合组(超声引导下前列腺内注射ICG-99mTc-纳米胶体,n=69)和序贯组(注射99mTc-纳米胶体,n=69),均在术前5小时给药。
  • 术前行淋巴显像和SPECT/CT定位前哨淋巴结,序贯组术中另注射游离ICG,所有(前哨)淋巴结在荧光引导下切除后行扩大盆腔淋巴结清扫。
  • 主要结局为手术切除的(前哨)淋巴结总数和肿瘤阳性(前哨)淋巴结数。

主要发现

  • 混合组与序贯组手术切除的(前哨)淋巴结包数分别为701和733(p=0.727)。
  • 混合组取出的荧光淋巴结为310枚,序贯组为665枚(p<0.001)。
  • 两组肿瘤阳性淋巴结数无统计学显著差异(44 vs 33;p=0.470)。
  • 混合组荧光淋巴结的肿瘤阳性率为7.4%,高于序贯组的2.6%(p=0.002)。
  • 术后90天内并发症两组无差异(p=0.78)。

关键数值与推荐

  • 淋巴受累风险采用2012年Briganti列线图评估,纳入风险>5%的患者。
  • 示踪剂于术前5小时经超声引导下前列腺内注射。
  • 主要结局指标为手术切除的(前哨)淋巴结总数和肿瘤阳性(前哨)淋巴结数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the diagnostic accuracy of the hybrid tracer indocyanine green (ICG)-Technetium-99 m(99mTc)-nanocolloid compared to sequential tracers of 99mTc-nanocolloid and free-ICG in detecting tumor-positive lymph nodes (LN) during primary surgery in prostate cancer (PCa) patients. INTRODUCTION: Image-guided surgery strategies can help visualize individual lymphatic drainage patterns and sentinel lymph nodes (SLNs) in PCa patients. For lymphatic mapping radioactive, fluorescent and hybrid tracers are being clinically exploited. In this prospective randomized phase II trial, we made a head-to-head comparison between ICG-99mTc-nanocolloid (hybrid group) and 99mTc-nanocolloid and subsequent free-ICG injection (sequential group). METHODS: PCa patients with a >5% risk of lymphatic involvement according to the 2012 Briganti nomogram and planned for prostatectomy were included and randomized (1:1) between ultrasound-guided intraprostatic tracer administration of ICG-99mTc-nanocolloid (n = 69) or 99mTc-nanocolloid (n = 69) 5 h before surgery. Preoperative lymphoscintigraphy and SPECT/CT were performed to define the locations of the SLNs. Additionally, all participants in the sequential group received an injection of free-ICG at time of surgery. Subsequently, all (S)LNs were dissected using fluorescence guidance followed by an extended pelvic lymph node dissection (ePLND). The primary outcome was the total number of surgically removed (S)LNs and tumor-positive (S)LNs. RESULTS: The total number of surgically removed (S)LN packages was 701 and 733 in the hybrid and sequential groups, respectively (p = 0.727). The total number of fluorescent LNs retrieved was 310 and 665 nodes in the hybrid and sequential groups, respectively (p < 0.001). However, no statistically significant difference was observed in the corresponding number of tumor-positive nodes among the groups (44 vs. 33; p = 0.470). Consequently, the rate of tumor-positive fluorescent LNs was higher in the hybrid group (7.4%) compared to the sequential group (2.6%; p = 0.002), indicating an enhanced positive predictive value for the hybrid approach. There was no difference in complications within 90 days after surgery (p = 0.78). CONCLUSIONS: The hybrid tracer ICG-99mTc-nanocolloid improved the positive predictive value for tumor-bearing LNs while minimizing the number of fluorescent nodes compared to the sequential tracer approach. Consequently, the hybrid tracer ICG-99mTc-nanocolloid enables the most reliable and minimal invasive method for LN staging in PCa patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wit EMK, KleinJan GH, Berrens AC, et al. A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2023. PMID: 37036490. doi:10.1007/s00259-023-06191-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。